Status:

COMPLETED

Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia

Lead Sponsor:

Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara

Collaborating Sponsors:

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Conditions:

Schizophrenia

Oxidative Stress

Eligibility:

All Genders

18-60 years

Phase:

PHASE2

PHASE3

Brief Summary

Schizophrenia is a devastating mental disorder with a prevalence of approximately 1% worldwide. While effective in reducing positive symptoms, current treatments have limited effects on cognitive and ...

Detailed Description

The underlying pathogenesis of schizophrenia remains unknown, but aberrant reduction-oxidation has gained increasing support as an hypothesis to help explain the pathophysiology of the disease. Alpha-...

Eligibility Criteria

Inclusion

  • Capacity to provide informed consent;
  • Schizophrenia diagnosis (made by research psychiatrists using the Structured Clinical Interview, SCID-5, for Diagnostic and Statistical Manual of Mental Disorders);
  • Negative and/or cognitive symptoms despite adequate antipsychotic treatment;
  • Ages 18-60 years

Exclusion

  • 6-month history of any drug or alcohol abuse or dependence;
  • Changes in psychotropic medications within the last 4 weeks;
  • Actual valproate use (potential interaction with ALA);
  • General medical illness including autoimmune disorders, known chronic infections such as HIV or hepatitis C, and liver or renal failure that could adversely impact on patient outcome;
  • Women who are planning to become pregnant, are pregnant, or are breastfeeding.

Key Trial Info

Start Date :

September 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2021

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT03788759

Start Date

September 1 2019

End Date

December 1 2021

Last Update

August 29 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Núcleo de Pesquisa e Desenvolvimento de Medicamentos - UFC

Fortaleza, Ceará, Brazil, 60430-275

Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia | DecenTrialz